FDA oncology division director
FDA appoints Robert Justice as director of the Division of Drug Oncology Products within FDA's Office of Oncology Drug Products, effective June 11. Justice had been acting director of the division since it became operational as part of a July 2005 CDER reorganization (1"The Pink Sheet" June 27, 2005, p. 11). Justice has held several positions within the agency since 1985 and was a senior clinical scientist at Genentech from 2000-2002...
You may also be interested in...
Deputy director of FDA's biological oncology product review team Robert Justice will head the Division of Drug Oncology Products under the reorganization of the Office of New Drugs
Teva has launched its generic version of NuvaRing in the US, adding a second rival generic to the market that already includes Amneal, as well as an authorized generic version from Prasco.
Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.